Elutia to Participate in Chardan’s Trending Issues in Drug Development Conference Series on April 29

Rhea-AI Summary

Elutia (Nasdaq: ELUT), a leader in drug-eluting biomatrix technologies, has announced its participation in Chardan's Trending Issues in Drug Development Conference Series. The company's Chief Scientific Officer, Dr. Michelle LeRoux Williams, will join a fireside chat discussion focused on 'Data & Regulatory Catalysts – Navigating an Evolving Landscape' on Tuesday, April 29, 2025, at 11:00 a.m. ET.

The virtual event will be accessible to investors and interested parties through a live webcast, with an archived version available afterward on the company's investor relations website at investors.elutia.com.

News Market Reaction – ELUT

+0.88%

+0.88% Session move

In the trading session that priced this news, ELUT gained 0.88%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SILVER SPRING, Md., April 22, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a pioneer in drug-eluting biomatrix technologies, today announced that Michelle LeRoux Williams, Ph.D., Elutia’s Chief Scientific Officer, will participate in Chardan’s Trending Issues in Drug Development Conference Series on Tuesday, April 29, 2025.

Chardan's Data & Regulatory Catalysts – Navigating an Evolving Landscape – Virtual
Format: Fireside Chat
Date and Time: Tuesday, April 29, 2025, 11:00 a.m. ET (8:00 a.m. PT)
Webcast: Click Here

A live and archived webcast of the fireside chat will be available in the “Investors” section of the Elutia website at http://investors.elutia.com/.

About Elutia
Elutia develops and commercializes drug-eluting biomatrix products to improve compatibility between medical devices and the patients who need them. With a growing population in need of implantable technologies, Elutia’s mission is humanizing medicine so patients can thrive without compromise. For more information, visit www.Elutia.com.

Investors:
Matt Steinberg
FINN Partners
matt.steinberg@finnpartners.com

This press release was published by a CLEAR® Verified individual.

FAQ

When is Elutia (ELUT) presenting at Chardan's Drug Development Conference 2025?

Elutia will participate in the conference on Tuesday, April 29, 2025, at 11:00 a.m. ET (8:00 a.m. PT).

What is the topic of Elutia's (ELUT) presentation at the Chardan Conference?

The presentation will be a fireside chat focusing on 'Data & Regulatory Catalysts – Navigating an Evolving Landscape.'

How can investors watch Elutia's (ELUT) Chardan Conference presentation?

Investors can watch the presentation through a live webcast available in the 'Investors' section of Elutia's website at investors.elutia.com.

Who will represent Elutia (ELUT) at the Chardan Conference 2025?

Dr. Michelle LeRoux Williams, Elutia's Chief Scientific Officer, will represent the company at the conference.